Skip to main content
SpringerLink
Log in

DTaP5-IPV-Hib Vaccine (Pediacel®)

Profile Report

  • Adis Profile Report
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Esposito S, Principi N. Differences in vaccinations in European Union. Hum Vaccin 2008; 4 (4): 313–5

    Article  PubMed  Google Scholar 

  2. United Nations Children’s Fund. Immunization summary: the 2007 edition [online]. Available from URL: http://www.unicef.org/publications/files/Immunization_Summary_2007.pdf [Accessed 2011 May 25]

  3. Dhillon S, Keam SJ. DTaP-IPV/Hib vaccine (Pentacel®). Pediatr Drugs 2008; 10 (6): 405–16

    Article  Google Scholar 

  4. Dhillon S. DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™): a review of its use as primary and booster vaccination. Drugs 2010 May 28; 70 (8): 1021–58

    Article  PubMed  CAS  Google Scholar 

  5. Sanofi Pasteur Limited. Quadracel® (diphtheria and tetanus toxoids, acellular pertussis adsorbed combined with inactivated poliomyelitis vaccine): suspension for injection. Product monograph [online]. Available from URL: https://www.vaccineshoppecanada.com/secure/pdfs/ca/quadrACEL_E.pdf [Accessed 2011 May 25]

  6. Infanrix-IPV (diphtheria, tetanus, pertussis [acellular component] and poliomyelitis [inactivated] vaccine [adsorbed]): summary of product characteristics. Uxbridge: GlaxoSmithKline, 2010

  7. Actacel™: concise prescribing information. Singapore: Zuellig Pharma, 2011

  8. Pediacel (diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine [adsorbed]): summary of product characteristics. Maidenhead: Sanofi Pasteur MSD Ltd, 2010

  9. Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate [tetanus toxoid conjugate]) vaccine: suspension for intramuscular injection (US prescribing information). Swiftwater (PA): Sanofi Pasteur Inc., 2009

  10. Pediarix (diphtheria and tetanus toxoids and acellular pertussis adsorbed, Hepatitis B [recombinant] and inactivated poliovirus vaccine): suspension for intramuscular injection (US prescribing information). Research Triangle Park (NC): GlaxoSmithKline Inc., 2010

  11. Infanrix-IPV+Hib (diphtheria, tetanus, pertussis [acellular component], poliomyelitis [inactivated] and Haemophilus type b conjugate vaccine [adsorbed]): summary of product characteristics. Uxbridge: GlaxoSmithKline, 2009

  12. Capeding MR, Cadorna-Carlos J, Book-Montellano M, et al. Immunogenicity and safety of a DTaP-IPV//PRP∼T combination vaccine given with hepatitis B vaccine: a randomized open-label trial. Bull WHO 2008; 86 (6): 443–51

    PubMed  Google Scholar 

  13. Pentavac® (diphtheria, tetanus, pertussis [acellular, component], poliomyelitis [inactivated] and Haemophilus influenzae type b conjugate vaccine [adsorbed]): summary of product characteristics. Brussels: Sanofi Pasteur MSD, 2010

  14. European Medicines Agency. Infanrix hexa™. Annex I: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000296/WC500032505.pdf [Accessed 2011 May 25]

  15. Grimprel E, Wysocki J, Boisnard F, et al. Immunogenicity and safety of fully liquid DTaP5-IPV-Hib compared with DTaP3-IPV/Hib when both coadministered with a heptavalent pneumococcal conjugate vaccine (PCV7) at 2, 3, and 4, and 12 to 18 months of age: a phase III, single-blind, randomized, controlled, multicentre study. Vaccine 2011; 29 (43): 7370–8

    Article  PubMed  CAS  Google Scholar 

  16. Lin TY, Wang YH, Chang LY, et al. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants. Int J Infect Dis 2007 Mar; 11 (2): 129–36

    Article  PubMed  CAS  Google Scholar 

  17. Wiedenmayer KA, Weiss S, Chattopadhyay C, et al. Simplifying paediatric immunization with a fully liquid DTP-HepB-Hib combination vaccine: evidence from a comparative time-motion study in India. Vaccine 2009; 27: 655–9

    Article  PubMed  CAS  Google Scholar 

  18. Andrews N, Stowe J, Wise L, et al. Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine 2010 Oct 18; 28 (44): 7215–20

    Article  PubMed  Google Scholar 

  19. Southern J, Borrow R, Andrews N, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009 Feb; 16 (2): 194–9

    Article  PubMed  CAS  Google Scholar 

  20. Moss SJ, Fenton AC, Toomey J, et al. Immunogenicity of a heptavalent conjugate pneumococcal vaccine administered concurrently with a combination diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type B vaccine and a meningococcal group C conjugate vaccine at 2, 3, and 4 months of age. Clin Vaccine Immunol 2010 Mar; 17 (3): 311–6

    Article  PubMed  CAS  Google Scholar 

  21. Medicines and Healthcare products Regulation Agency. Public assessment report decentralized procedure: Pediacel suspension for injection in pre-filled syringe [procedure no.: UK/H/2388/01/DC; UK licence no.: PL 06745/0128; online]. Available from URL: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con108611.pdf [Accessed 2011 May 22]

  22. Vesikari T, Silfverdal SA, Boisnard F, et al. Immunogenicity and safety of a fully liquid DTaP5-IPV-Hib versus DTaP3-IPV/Hib at 3, 5, and 12 months of age [abstract plus poster]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4–8; Nice

  23. Kitchin NR, Southern J, Morris R, et al. Evaluation of a diphtheria-tetanusacellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 2007 Jan; 92 (1): 11–6

    Article  PubMed  CAS  Google Scholar 

  24. Kitchin N, Southern J, Morris R, et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine 2009 Aug 13; 27 (37): 5096–102

    Article  PubMed  CAS  Google Scholar 

  25. Gold R, Barreto L, Ferro S, et al. Safety and immunogenicity of a fully liquid vaccine containing five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis-Haemophilus influenzae type b conjugate vaccines administered at two, four, six and 18 months of age. Can J Infect Dis Med Microbiol 2007 Jul; 18 (4): 241–8

    PubMed  Google Scholar 

  26. Berner R, Boisnard F, Thomas S, et al. Safety and immunogenicity of fully liquid DTaP5-IPV-Hib versus DTaP3-HBV-IPV/Hib as a booster at 11–18 months of age coadministered with PCV7 [abstract plus poster]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; 2010 May 4–8; Nice

  27. Sanofi Pasteur Limited. Pediacel® (diphtheria and tetanus toxoids, acellular pertussis adsorbed combined with inactivated poliomyelitis vaccine and Haemophilus b conjugate vaccine [tetanus protein - conjugate]) — suspension for injection: product monograph [online]. Available from URL: https://www.vaccineshoppecanada.com/secure/pdfs/ca/Pediacel_E.pdf [Accessed 2011 Jun 13]

  28. Lin TY, Wang YH, Huang YC, et al. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. Int J Infect Dis 2007 Nov; 11 (6): 488–95

    Article  PubMed  CAS  Google Scholar 

  29. Capeding MR, Unalivia L, Victorio MV, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-Hib vaccine in infants at 6, 10, 14 weeks of age (EPI schedule) [poster]. 3rd World Congress of Pediatric Infectious Diseases (WSPID); 2002 Nov 19–23; Santiago

  30. Castaneda JL, Gonzalez N, Chavez R, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-Hib vaccine with full primary IPV or sequential IPV-OPV in Mexican infants [poster]. 11th International Congress on Infectious Diseases (ICID); 2004 Mar 4–7; Cancun

  31. Klinger CL, Snape MD, John T, et al. Immunogenicity of DTaP-IPV-Hib and MenC vaccines in the UK when administered with a 13-valent pneumococcal conjugate vaccine [abstract no. GI-2118]. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, and 46th Annual Meeting of the Infectious Diseases Society of America — a joint meeting; 2008 Oct 25–28; Washington, DC

  32. Frampton JE. DTaP5-IPV-Hib Vaccine (Pediacel®). Pediatr Drugs 2011; 13 (6): 401–15

    Article  Google Scholar 

Download references

Acknowledgments and Disclosures

The full text article[32] from which this profile report was derived was reviewed by: R.R. Borrow, Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, UK; S. Esposito, Department of Maternal and Pediatric Sciences, University of Milan, Milan, Italy. iG. Gabutti, Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy; S. Ladhani; Immunisation Department, Centre for Infections, Health Protection Agency, London, UK; E. Miller, Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, UK.

The manufacturer of the agent under review was offered an opportunity to comment on the original article during the peer review process. Changes based on any comments received were made by the author on the basis of scientific and editorial merit. The preparation of the original article and this profile report was not supported by external funding.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Additional information

Adapted and reproduced from the original article published in Pediatric Drugs 2011; 13 (6): 401–15

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frampton, J.E. DTaP5-IPV-Hib Vaccine (Pediacel®). BioDrugs 26, 121–123 (2012). https://doi.org/10.2165/11608730-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11608730-000000000-00000

Keywords

Search

Navigation